Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations

A prospective study of 312 patients [194 with multiple myeloma (MM) and 118 with lymphomas (LYMPH)] receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT) was conducted. Ficolins are innate immune defense factors, able to distinguish between “self” “abnormal self,” and “non-self” and contribute to the elimination of the last two by direct opsonization and/or initiation of complement activation via the lectin pathway. Concentrations of ficolin-1, ficolin-2, and ficolin-3 in serially taken serum samples were determined as were the polymorphisms of the corresponding (FCN1, FCN2, and FCN3) genes. Serum samples were collected before conditioning chemotherapy, before HSCT, and once weekly post-HSCT (four to five samples in total); some patients were also sampled at 1 and/or 3 months post-transplantation. The control group (C) consisted of 267 healthy unrelated individuals. Median ficolin-1 and ficolin-2 (but not ficolin-3) levels in MM patients' sera taken before chemotherapy were lower (and correspondingly frequencies of the lowest concentrations were higher) compared with controls. That appeared to be associated with the malignant disease itself rather than with post-HSCT complications (febrile neutropenia, infections accompanied, or not with bacteremia). Higher frequencies of the FCN1 genotype G/A-C/C-G/G (corresponding to polymorphisms at positions −542, −144, and +6658, respectively) and FCN2 gene heterozygosity for the −857 C>A polymorphism were found among patients diagnosed with MM compared with the C group. Furthermore, FCN2 G/G homozygosity (−557 A>G) was found more frequently and heterozygosity G/T at +6424 less frequently among LYMPH patients than among the healthy subjects. Heterozygosity for +1637delC mutation of the FCN3 gene was more common among patients diagnosed with lymphomas who experienced hospital infections. Although no evidence for an association of low ficolin-1 or ficolin-2 with infections during neutropenia following chemotherapy before HSCT was found, we observed a possible protective effect of ficolins during follow-up.

[1]  N. Majhail,et al.  Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era , 2019, Clinical lymphoma, myeloma & leukemia.

[2]  S. Sawicki,et al.  Interactions of ficolin-3 with ovarian cancer cells. , 2019, Immunobiology.

[3]  A. Nerlich,et al.  Presence of Infected Gr-1intCD11bhiCD11cint Monocytic Myeloid Derived Suppressor Cells Subverts T Cell Response and Is Associated With Impaired Dendritic Cell Function in Mycobacterium avium-Infected Mice , 2018, Front. Immunol..

[4]  J. Espinoza,et al.  Infection Complications in Hematopoietic Stem Cells Transplant Recipients: Do Genetics Really Matter? , 2018, Front. Microbiol..

[5]  M. Kowalski,et al.  The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT) , 2018, Front. Immunol..

[6]  M. Markiewski,et al.  Complementing Cancer Metastasis , 2018, Front. Immunol..

[7]  R. Ambinder,et al.  Hodgkin lymphoma: A review and update on recent progress , 2018, CA: a cancer journal for clinicians.

[8]  Quanquan Ding,et al.  Ficolin-2 triggers antitumor effect by activating macrophages and CD8+ T cells. , 2017, Clinical immunology.

[9]  Xiang-Yu Liu,et al.  Recent progress in the understanding of complement activation and its role in tumor growth and anti-tumor therapy. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  J. Lambert,et al.  Non-Hodgkin lymphoma , 2017, Medicine.

[11]  S. Thiel,et al.  Lectin complement pathway proteins in healthy individuals , 2017, Clinical and experimental immunology.

[12]  M. A. Abu Zaid,et al.  Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. , 2017, Blood.

[13]  B. Ferhanoğlu,et al.  Early Changes of Mannose-Binding Lectin, H-Ficolin, and Procalcitonin in Patients with Febrile Neutropenia: A Prospective Observational Study , 2016, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[14]  A. Tefferi.  CME Information , 2016, Stahl's Illustrated Sleep and Wake Disorders.

[15]  R. Kennedy,et al.  Ficolin-2 inhibitors are present in sera after prolonged storage at −80 °C , 2016, PeerJ.

[16]  A. Blom,et al.  Complement in removal of the dead – balancing inflammation , 2016, Immunological reviews.

[17]  M. Ratajczak,et al.  Novel evidence that the mannan-binding lectin pathway of complement activation plays a pivotal role in triggering mobilization of hematopoietic stem/progenitor cells by activation of both the complement and coagulation cascades , 2016, Leukemia.

[18]  P. Hari,et al.  Recent advances in understanding multiple myeloma , 2016, F1000Research.

[19]  Ying-jian Liang,et al.  FCN2 inhibits epithelial-mesenchymal transition-induced metastasis of hepatocellular carcinoma via TGF-β/Smad signaling. , 2016, Cancer letters.

[20]  M. Matsushita,et al.  Components of the lectin pathway of complement activation in paediatric patients of intensive care units. , 2016, Immunobiology.

[21]  S. Hanash,et al.  Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  M. Mikulska,et al.  Bacterial Infections in Hematopoietic Stem Cell Transplant Recipients , 2015, Mediterranean journal of hematology and infectious diseases.

[23]  Qingchuan Zhao,et al.  A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro , 2015, Scientific Reports.

[24]  D. Kyriakidis,et al.  Mannose binding lectin and ficolin‐2 polymorphisms are associated with increased risk for bacterial infections in children with B acute lymphoblastic leukemia , 2014, Pediatric blood & cancer.

[25]  A. Parsa,et al.  Complement anaphylatoxins as immune regulators in cancer , 2014, Cancer medicine.

[26]  P. Garred,et al.  Ficolin-2 reveals different analytical and biological properties dependent on different sample handling procedures. , 2013, Molecular immunology.

[27]  A. Falsey,et al.  Blood Collection Tubes Influence Serum Ficolin-1 and Ficolin-2 Levels , 2013, Clinical and Vaccine Immunology.

[28]  M. Matsushita,et al.  The relationship between FCN2 genotypes and serum ficolin-2 (L-ficolin) protein concentrations from a large cohort of neonates. , 2013, Human immunology.

[29]  M. Cedzyński,et al.  Cost-effective procedures for genotyping of human FCN2 gene single nucleotide polymorphisms , 2013, Immunogenetics.

[30]  H. Baba,et al.  Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88) , 2013, Clinical Cancer Research.

[31]  H. Nielsen,et al.  Non-Synonymous Polymorphisms in the FCN1 Gene Determine Ligand-Binding Ability and Serum Levels of M-Ficolin , 2012, PloS one.

[32]  John D Lambris,et al.  Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression , 2012, The Journal of Immunology.

[33]  John D Lambris,et al.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. , 2012, Neoplasia.

[34]  M. Matsushita,et al.  H-ficolin (ficolin-3) concentrations and FCN3 gene polymorphism in neonates. , 2012, Immunobiology.

[35]  S. Thiel,et al.  M‐ficolin levels are associated with the occurrence of severe infections in patients with haematological cancer undergoing chemotherapy , 2012, Clinical and experimental immunology.

[36]  S. Thiel,et al.  M-ficolin in children with cancer. , 2011, Immunobiology.

[37]  J. Badimón,et al.  The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP‐1 and MMP‐9 in human macrophages in vitro , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  M. Sughrue,et al.  The complement cascade as a mediator of tissue growth and regeneration , 2010, Inflammation Research.

[39]  C. Mackay,et al.  The C5a Receptor (C5aR) C5L2 Is a Modulator of C5aR-mediated Signal Transduction* , 2009, The Journal of Biological Chemistry.

[40]  P. Garred,et al.  Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. , 2009, The New England journal of medicine.

[41]  J. Jensenius,et al.  H‐ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients , 2009, Clinical and experimental immunology.

[42]  John D Lambris,et al.  Is complement good or bad for cancer patients? A new perspective on an old dilemma. , 2009, Trends in immunology.

[43]  H. Nielsen,et al.  Characteristics and Biological Variations of M-Ficolin, a Pattern Recognition Molecule, in Plasma , 2009, Journal of Innate Immunity.

[44]  N. Sheerin,et al.  C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. , 2009, Journal of the American Society of Nephrology : JASN.

[45]  Robert B Sim,et al.  Comparative study of the human ficolins reveals unique features of Ficolin-3 (Hakata antigen). , 2008, Molecular immunology.

[46]  M. Turner,et al.  Extremes of l‐ficolin concentration in children with recurrent infections are associated with single nucleotide polymorphisms in the FCN2 gene , 2007, Clinical and experimental immunology.

[47]  P. Cohen,et al.  CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway. , 2006, Cellular signalling.

[48]  M. Munakata,et al.  Human M-Ficolin Is a Secretory Protein That Activates the Lectin Complement Pathway1 , 2005, The Journal of Immunology.

[49]  T. Fujita,et al.  Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. , 2005, Human molecular genetics.

[50]  C. van Broeckhoven,et al.  novoSNP, a novel computational tool for sequence variation discovery. , 2005, Genome research.

[51]  M. Turner,et al.  No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy‐related infections , 2003, Clinical and experimental immunology.

[52]  Randy D Gascoyne,et al.  Non-Hodgkin lymphoma , 2016, Medicine.

[53]  H. Rus,et al.  Role of the C5b‐9 complement complex in cell cycle and apoptosis , 2001, Immunological reviews.

[54]  Satoshi O. Suzuki,et al.  Hakata Antigen, a New Member of the Ficolin/Opsonin p35 Family, Is a Novel Human Lectin Secreted into Bronchus/Alveolus and Bile , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[55]  K. Okochi,et al.  Cloning and Characterization of the Hakata Antigen, a Member of the Ficolin/Opsonin p35 Lectin Family* , 1998, The Journal of Biological Chemistry.

[56]  T. Fujita,et al.  Cloning and characterization of the human lectin P35 gene and its related gene. , 1996, Genomics.

[57]  H. Rus,et al.  Sublytic complement attack induces cell cycle in oligodendrocytes. , 1996, Journal of immunology.

[58]  T. Fujita,et al.  A Novel Human Serum Lectin with Collagen- and Fibrinogen-like Domains That Functions as an Opsonin (*) , 1996, The Journal of Biological Chemistry.

[59]  M. Kirschfink,et al.  The complement system in cancer: Ambivalence between tumour destruction and promotion. , 2017, Immunobiology.

[60]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[61]  H. Rus,et al.  The role of C5b-9 terminal complement complex in activation of the cell cycle and transcription , 2005, Immunologic research.

[62]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.